Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
Avidity Biosciences to Participate in Upcoming Investor Conferences
09:00am, Tuesday, 25'th Feb 2025
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 21'st Feb 2025
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 20'th Jan 2025
SAN DIEGO , Jan. 20, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 08'th Jan 2025
SAN DIEGO , Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
09:00am, Wednesday, 08'th Jan 2025
Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025 On track to complete enrollment in del-desiran HARBOR TM Phase 3 and pote
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 20'th Dec 2024
SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases
09:25am, Wednesday, 11'th Dec 2024
Avidity Biosciences' AOC platform targets genetic diseases by combining monoclonal antibodies with oligonucleotide therapies, overcoming traditional delivery limitations. Del-brax (AOC 1020) for FSHD
Avidity Biosciences to Participate in Upcoming Investor Conference
10:00am, Tuesday, 26'th Nov 2024
SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st Nov 2024
SAN DIEGO , Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
RNA Stock Hits Record High on Entering the Cardiac Disease Space
09:41am, Thursday, 14'th Nov 2024
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
11:24am, Wednesday, 13'th Nov 2024
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. The post Avidity Bio Has Surged 416% This Year — And That's Before Toda
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomy
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
07:10pm, Thursday, 07'th Nov 2024
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.71 per share a year ago.
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
04:05pm, Thursday, 07'th Nov 2024
Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval p
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
11:05am, Wednesday, 06'th Nov 2024
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
